(0.09%) 5 522.00 points
(0.12%) 39 891 points
(0.22%) 19 794 points
(0.01%) $81.64
(0.46%) $2.82
(-0.32%) $2 336.80
(-0.03%) $29.52
(0.21%) $1 003.90
(0.02%) $0.932
(-0.02%) $10.53
(0.01%) $0.788
(-0.85%) $87.25
-0.21% $ 37.41
Live Chart Being Loaded With Signals
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada...
Stats | |
---|---|
Dzisiejszy wolumen | 270 822 |
Średni wolumen | 358 414 |
Kapitalizacja rynkowa | 2.82B |
EPS | $-0.620 ( Q1 | 2024-05-09 ) |
Następna data zysków | ( $0 ) 2024-08-07 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-13.75 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.0200 (0.05%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-06-05 | Patou Gary | Buy | 15 542 | Stock Option (Right to Buy) |
2024-06-05 | Machado Patrick | Buy | 15 542 | Stock Option (Right to Buy) |
2024-06-05 | Gover Justin D. | Buy | 15 542 | Stock Option (Right to Buy) |
2024-06-05 | Garofalo Elizabeth A. | Buy | 15 542 | Stock Option (Right to Buy) |
2024-06-05 | Gannon Steven | Buy | 15 542 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
65.50 |
Last 100 transactions |
Buy: 2 285 491 | Sell: 531 159 |
Wolumen Korelacja
Xenon Pharmaceuticals Inc Korelacja
10 Najbardziej pozytywne korelacje | |
---|---|
ZS | 0.893 |
IRWD | 0.887 |
DMRC | 0.873 |
TNGX | 0.872 |
WRAP | 0.868 |
TACT | 0.862 |
TBBK | 0.862 |
MDB | 0.861 |
ASUR | 0.86 |
NEPH | 0.858 |
10 Najbardziej negatywne korelacje | |
---|---|
TIGO | -0.885 |
IGLD | -0.877 |
GLDI | -0.865 |
MRVI | -0.845 |
BZFD | -0.844 |
PPC | -0.843 |
SLVO | -0.843 |
KNTK | -0.842 |
SANG | -0.841 |
KALU | -0.84 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Xenon Pharmaceuticals Inc Korelacja - Waluta/Towar
Xenon Pharmaceuticals Inc Finanse
Annual | 2023 |
Przychody: | $0 |
Zysk brutto: | $-3.54M (0.00 %) |
EPS: | $-2.73 |
FY | 2023 |
Przychody: | $0 |
Zysk brutto: | $-3.54M (0.00 %) |
EPS: | $-2.73 |
FY | 2022 |
Przychody: | $9.43M |
Zysk brutto: | $-96.33M (-1 021.13 %) |
EPS: | $-2.07 |
FY | 2021 |
Przychody: | $18.44M |
Zysk brutto: | $0.00 (0.00 %) |
EPS: | $-1.770 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Xenon Pharmaceuticals Inc
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other potential indications, including adult focal epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop PCRX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej